MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to ...

The SNU BioTalk 2025 an International Conference, themed "Symphony of Cellular Signals in Metabolism and Immune Response," ...